Affinage

ELOVL3

Very long chain fatty acid elongase 3 · UniProt Q9HB03

Length
270 aa
Mass
31.5 kDa
Annotated
2026-06-09
22 papers in source corpus 18 papers cited in narrative 18 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ELOVL3 is a microsomal fatty acid elongase that catalyzes the condensation step extending saturated and monounsaturated fatty acyl-CoAs into very long chain fatty acids (C20–C24+), governing neutral lipid composition across sebaceous glands, brown and white adipose tissue, liver, and meibomian glands (PMID:14581464, PMID:16326704, PMID:20605947). Genetic ablation eliminates fatty acids beyond C20 in skin/hair triglycerides and abolishes cold-induced condensation activity for C20:0/C22:0 synthesis in brown adipose tissue, establishing its direct catalytic role (PMID:14581464, PMID:16326704). The VLCFAs it produces are functionally indispensable: in meibomian glands they generate the C21–C29 species (including odd- and branched-chain) of cholesteryl and wax esters that set meibum melting temperature and fluidity (PMID:31208226, PMID:33455016), and in brown adipose tissue they sustain lysophosphatidylcholine, cardiolipin, and acylcarnitine pools required for UCP1 expression, mitochondrial cristae remodeling, and cold-adaptive thermogenesis (PMID:41202879). ELOVL3-derived VLCFAs also support hepatic triglyceride synthesis, VLDL-TG secretion, and adipose lipid storage, with the systemic anti-obesity phenotype of global knockouts traced to extrahepatic ELOVL3, since hepatocyte-specific deletion leaves liver lipid homeostasis intact (PMID:20605947, PMID:37030067). Transcription of ELOVL3 is integrated by a dense regulatory network: it is induced by PPARγ acting through promoter PPREs during adipogenesis—with ELOVL3-derived C18:1/C20:1 feeding back as PPARγ agonists in a positive loop (PMID:22436697)—and by PPARα with sympathetic input in brown adipocytes (PMID:15855229, PMID:17726147), while being controlled circadianly by SREBP1, NR1D1/RevErbα, and BMAL1 in coordination with androgen signaling (PMID:17003504, PMID:30862677), and repressed by VDR and androgen receptor through dedicated promoter response elements (PMID:26488808, PMID:39123669); additional inputs include RORγ–BRG1–p300 epigenetic co-activation and the transcription factor ZHX2, the latter linking ELOVL3 to control of hepatocyte cell-cycle progression (PMID:31154107, PMID:37847682).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2003 High

    Established that ELOVL3 is the elongase responsible for synthesizing C20+ fatty acids in skin/hair neutral lipids, defining its core enzymatic identity.

    Evidence Elovl3 knockout mice with hair/triglyceride fatty acid profiling and trans-epidermal water loss measurement

    PMID:14581464

    Open questions at the time
    • Did not establish substrate chain-length specificity by in vitro assay
    • Did not address roles outside the pilosebaceous system
  2. 2005 High

    Demonstrated direct catalytic condensation activity of ELOVL3 on saturated acyl-CoAs in brown adipose tissue and linked it to cold-stress thermogenesis, extending its function beyond skin.

    Evidence In vitro elongation condensation assay on BAT extracts from knockout mice plus cold acclimation phenotyping

    PMID:16326704

    Open questions at the time
    • Did not resolve the molecular basis of the thermogenic deficit
    • Tissue-autonomy of the BAT requirement not established
  3. 2005 Medium

    Placed ELOVL3 in a PPARα-driven, oxidative transcriptional program distinct from LXR/SREBP-1-driven lipogenesis in brown adipocytes.

    Evidence Pharmacological ligand treatments in primary brown adipocytes with mRNA and esterified lipid analysis

    PMID:15855229

    Open questions at the time
    • No direct promoter occupancy demonstrated
    • Single lab pharmacological inference
  4. 2006 Medium

    Connected ELOVL3 transcription to circadian and nutritional control via SREBP1 activation and RevErbα repression at its promoter.

    Evidence CLOCK-mutant mouse liver analysis with SREBP1/RevErbα promoter reporter assays and meal-restriction experiments

    PMID:17003504

    Open questions at the time
    • In vivo direct binding not shown in this study
    • Functional lipid consequence of clock disruption not measured
  5. 2007 Medium

    Showed ELOVL3 induction integrates sympathetic and PPARγ signals through both transcription and mRNA stabilization in brown adipocytes.

    Evidence Norepinephrine/rosiglitazone treatment of primary brown adipocytes with mRNA stability and cycloheximide experiments

    PMID:17726147

    Open questions at the time
    • Did not identify the labile protein required for induction
    • mRNA stabilization mechanism unresolved
  6. 2008 Medium

    Revealed sexually dimorphic, hormonally controlled circadian regulation of hepatic ELOVL3 and cross-talk with peroxisomal VLCFA oxidation via ABCD2.

    Evidence Time-series mRNA profiling, dexamethasone injection, castration, and ABCD2 knockout/transgenic mouse models

    PMID:18292190

    Open questions at the time
    • Direct promoter targets of glucocorticoid/androgen not mapped here
    • Mechanism of ELOVL3–ABCD2 cross-talk not defined
  7. 2010 High

    Defined ELOVL3 as a determinant of systemic lipid handling—hepatic de novo synthesis, VLDL-TG secretion, and adipose expansion—broadening its role to whole-body energy storage.

    Evidence Global knockout mice under diet-induced obesity with in vivo fatty acid synthesis, VLDL-TG secretion assays, and tissue histology

    PMID:20605947

    Open questions at the time
    • Did not resolve which tissue drives the systemic phenotype
    • Mechanism linking VLCFA to TG synthesis not detailed
  8. 2012 High

    Established a feed-forward loop in which PPARγ directly activates ELOVL3 and ELOVL3-derived C18:1/C20:1 VLCFAs act as PPARγ agonists to sustain adipogenesis.

    Evidence ChIP, PPRE-mutant promoter reporters, mammalian two-hybrid, and siRNA rescue in 3T3-L1 cells

    PMID:22436697

    Open questions at the time
    • Endogenous VLCFA-PPARγ binding affinity not quantified
    • Loop dynamics in vivo not established
  9. 2015 Medium

    Identified ELOVL3 as a direct VDR repression target controlling fatty acid composition specifically in subcutaneous white adipose tissue.

    Evidence VDR knockout mice with ChIP at a promoter negative-response element and depot-specific lipid profiling

    PMID:26488808

    Open questions at the time
    • Physiological trigger for VDR-mediated repression unclear
    • Depot specificity mechanism unexplained
  10. 2019 Medium

    Demonstrated epigenetic co-activation of ELOVL3 by a RORγ–BRG1–p300 complex in prostate cancer cells responding to androgen and TGF-β.

    Evidence BRG1/p300 ChIP, reciprocal Co-IP with RORγ, p300 inhibition, and migration/invasion assays in prostate cancer cells

    PMID:31154107

    Open questions at the time
    • Functional contribution of ELOVL3 lipids to cancer phenotype not established
    • Single lab; cancer-cell context only
  11. 2019 High

    Defined ELOVL3's essential catalytic role in meibogenesis, producing the long and odd/branched-chain fatty acids of meibum lipid esters.

    Evidence Knockout mice with mass spectrometric lipidomics of tarsal plate lipids

    PMID:31208226

    Open questions at the time
    • Functional/optical consequence for tear film not yet measured here
    • Substrate preference among classes not resolved
  12. 2019 High

    Showed sustained rhythmic hepatic ELOVL3 expression requires coordinated BMAL1 circadian and androgen-receptor signaling, with direct NR1D1 promoter binding.

    Evidence Bmal1 knockout, circadian NR1D1 ChIP, castration/DHT replacement in vivo, and flutamide treatment in AML12 cells

    PMID:30862677

    Open questions at the time
    • Integration of androgen and clock inputs at promoter not fully mechanistic
    • Downstream lipid consequence of rhythm loss unaddressed
  13. 2021 Medium

    Connected ELOVL3-derived VLCFAs to the physical properties of meibum, showing loss lowers melting temperature and dysregulates gland gene networks.

    Evidence Knockout mice with heat-stage polarized light microscopy of meibum melting and meibomian gland RNA-seq

    PMID:33455016

    Open questions at the time
    • Causal link between specific lipid species and melting behavior not isolated
    • In vivo tear-film clinical consequences not measured
  14. 2023 Medium

    Identified ZHX2 as a positive transcriptional regulator and linked ELOVL3-derived VLCFAs to control of hepatocyte cell-cycle progression.

    Evidence Zhx2-null mouse livers, liver regeneration models, and hepatoma overexpression with cell cycle and cyclin analysis

    PMID:37847682

    Open questions at the time
    • Mechanism linking VLCFA to S-phase arrest unresolved
    • ZHX2 promoter binding not directly demonstrated
  15. 2023 Medium

    Showed hepatocyte-autonomous ELOVL3 is dispensable for liver lipid homeostasis, attributing the global-KO anti-obesity phenotype to extrahepatic ELOVL3.

    Evidence Liver-specific Cre/LoxP knockout with high-fat challenge, lipidomics, and comprehensive metabolic phenotyping

    PMID:37030067

    Open questions at the time
    • Did not identify which extrahepatic tissue drives the systemic phenotype
    • Possible compensation by other elongases not fully excluded
  16. 2024 Medium

    Demonstrated direct androgen-receptor repression of ELOVL3 through a promoter ARE and its requirement for preadipocyte lipid droplet accumulation.

    Evidence ARE-mutant dual-luciferase reporters, AR overexpression, and siRNA knockdown with lipid droplet staining in porcine preadipocytes

    PMID:39123669

    Open questions at the time
    • Conservation of ARE regulation across species not established
    • Mechanism linking ELOVL3 to FASN/ATGL changes unclear
  17. 2025 High

    Established BAT-autonomous ELOVL3 as essential for cold thermogenesis via maintenance of phospholipid pools supporting UCP1 and mitochondrial cristae remodeling.

    Evidence BAT-specific Cre/LoxP knockout with cold challenge, lipidomics, UCP1 expression, and mitochondrial ultrastructure

    PMID:41202879

    Open questions at the time
    • Direct biochemical link between specific VLCFA species and cristae architecture not isolated
    • Cardiolipin remodeling mechanism not defined
  18. 2026 Medium

    Placed ELOVL3 downstream of a USP25–PARP1 axis driving preadipocyte differentiation, adding a deubiquitination-dependent regulatory layer.

    Evidence Usp25 knockout mice, USP25–PARP1 Co-IP and ubiquitination assays, and PARP1 knockdown with Elovl3 readout in 3T3-L1 cells

    PMID:41692245

    Open questions at the time
    • ELOVL3 placement is inferred downstream of PARP1, not directly mechanistic
    • Whether PARP1 acts on the ELOVL3 promoter is not shown

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis of ELOVL3 substrate selectivity and the precise mechanism by which its VLCFA products shape membrane phospholipid architecture and signaling remain unresolved.
  • No structural model of the enzyme
  • Substrate-specificity determinants not mapped
  • Mechanism by which VLCFAs alter cristae and PPARγ activity not biochemically defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5
Localization
GO:0005783 endoplasmic reticulum 1
Pathway
R-HSA-1430728 Metabolism 4 R-HSA-74160 Gene expression (Transcription) 4

Evidence

Reading pass · 18 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 ELOVL3 is a microsomal enzyme required for elongation of fatty acids beyond 20 carbons; disruption of the Elovl3 gene in mice causes near-complete absence of fatty acids >20 carbons in triglycerides (especially in the skin/hair), with accumulation of eicosenoic acid (20:1), establishing ELOVL3 as the elongase responsible for C20+ neutral lipid fatty acid synthesis in sebaceous glands and hair follicle epithelial cells. Elovl3 gene knockout by homologous recombination in mouse; fatty acid profiling of hair lipids and triglyceride fractions; histological analysis of pilosebaceous system; trans-epidermal water loss measurement The Journal of biological chemistry High 14581464
2005 ELOVL3 is required for elongation of saturated fatty acyl-CoAs into very long chain fatty acids (C20:0, C22:0) in brown adipose tissue; Elovl3-ablated mice show decreased condensation activity of the elongation enzyme and reduced arachidic and behenic acid levels during cold stress, establishing ELOVL3 as a critical elongase for saturated VLCFA synthesis and triglyceride formation in BAT during early tissue recruitment. Elovl3 knockout mice; cold acclimation protocol; in vitro elongation condensation activity assay on BAT extracts; fatty acid composition analysis; body temperature monitoring; muscle shivering measurement The Journal of biological chemistry High 16326704
2005 Elovl3 expression in brown adipocytes is transcriptionally controlled by PPARα (induced by PPARα ligand Wy-14643 in concert with norepinephrine and dexamethasone), while LXR/SREBP-1 activation represses Elovl3 expression and increases Elovl1; this differential regulation establishes ELOVL3 in a distinct transcriptional program linked to oxidative (non-lipogenic) metabolic states, functionally reflected in C22:0 esterified fatty acid levels. Primary brown adipocyte cultures; PPARα/LXRα ligand treatments; mRNA expression analysis; nuclear LXR and SREBP-1 abundance measurement; fatty acid composition analysis of esterified lipids American journal of physiology. Endocrinology and metabolism Medium 15855229
2006 Circadian expression of Elovl3 in mouse liver is perturbed in CLOCK-mutant mice and is activated by SREBP1 and repressed by RevErbα at the Elovl3 promoter; proteolytic activation of SREBP1 is itself circadian in the liver and responds to meal timing, placing ELOVL3 downstream of a clock–nutrition integration mechanism. CLOCK mutant mouse liver analysis; promoter reporter assays with SREBP1 and RevErbα; meal-restriction experiments with inverted feeding; hepatic dysfunction mouse model Journal of lipid research Medium 17003504
2007 Elovl3 expression in brown adipocytes is synergistically induced by norepinephrine and the PPARγ ligand rosiglitazone; this induction requires novel protein synthesis, is achieved through both increased transcription and increased mRNA stability, and rosiglitazone is orders of magnitude more potent than PPARα or PPARδ ligands, placing ELOVL3 downstream of PPARγ and sympathetic activation in brown adipocyte lipid accumulation. Primary brown adipocyte cultures; norepinephrine and rosiglitazone (PPARγ agonist) treatment; quantitative mRNA analysis; mRNA stability assay; protein synthesis inhibitor (cycloheximide) treatment; comparison with PPARα and PPARδ ligands American journal of physiology. Endocrinology and metabolism Medium 17726147
2008 Hepatic Elovl3 expression follows a sexually dimorphic circadian rhythm controlled by glucocorticoids and androgens; dexamethasone (synthetic glucocorticoid) transcriptionally induces Elovl3 in mouse liver, and expression is elevated in ABCD2-ablated mice and suppressed in ABCD2-overexpressing mice, revealing cross-talk between VLCFA synthesis (ELOVL3) and peroxisomal VLCFA oxidation (ABCD2). Zeitgeber time-series mRNA analysis in male/female/immature mice; fasting/refeeding and restricted feeding experiments; dexamethasone injection; ABCD2 knockout and transgenic overexpression mouse models; castration experiments Endocrinology Medium 18292190
2010 ELOVL3 synthesizes C20–C24 saturated and monounsaturated VLCFAs in liver, brown and white adipose tissue, and triglyceride-rich glands; ablation reduces hepatic de novo fatty acid synthesis, fatty acid uptake, triglyceride content, and VLDL-triglyceride secretion, and constrains adipose tissue expansion, demonstrating that ELOVL3-derived VLCFAs are required for hepatic triglyceride synthesis and adipose lipid storage. Global Elovl3 knockout mice; diet-induced obesity model; hepatic lipogenic gene expression analysis; in vivo de novo fatty acid synthesis measurement; VLDL-TG secretion assay; serum adiponectin and leptin measurement; adipose tissue histology FASEB journal High 20605947
2012 PPARγ directly binds three PPAR-responsive elements in the Elovl3 promoter to activate transcription during adipogenesis; C18:1 and C20:1 VLCFAs produced by ELOVL3 act as PPARγ agonists (coactivator recruitment in mammalian two-hybrid assay), creating a positive feedback loop (ELOVL3–VLCFA–PPARγ) that sustains adipogenic gene expression. 3T3-L1 adipogenesis model; Elovl3 siRNA knockdown; promoter-reporter assays with PPRE mutations; chromatin immunoprecipitation (ChIP) for PPARγ at Elovl3 promoter; mammalian two-hybrid assay for C18:1 and C20:1 activation of PPARγ; PPARγ antagonist rescue experiment American journal of physiology. Endocrinology and metabolism High 22436697
2015 Vitamin D receptor (VDR) directly occupies a negative-response element in the proximal Elovl3 promoter in a ligand-dependent manner, transcriptionally repressing Elovl3 expression specifically in subcutaneous white adipose tissue; VDR deletion leads to increased C18–C24 saturated and monounsaturated fatty acids in sc WAT, placing ELOVL3 as a direct VDR target responsible for tissue-specific fatty acid composition. VDR knockout (VDRKO) mice; fatty acid composition analysis of sc and visceral WAT depots; ChIP assay for VDR occupancy at Elovl3 promoter negative-response element; in vivo vitamin D treatment; tissue-specific gene expression analysis Endocrinology Medium 26488808
2019 BRG1 (chromatin remodeling ATPase) is recruited by the nuclear receptor RORγ to the Elovl3 promoter to activate transcription in prostate cancer cells in response to androgen and TGF-β; BRG1 also interacts with histone acetyltransferase p300 at the Elovl3 promoter, and p300 inhibition or depletion attenuates Elovl3 trans-activation, linking ELOVL3 expression to BRG1–RORγ–p300 epigenetic co-activation. BRG1 overexpression and knockdown in prostate cancer cells; Elovl3 promoter ChIP assay for BRG1 and p300; Co-immunoprecipitation of BRG1 with RORγ; siRNA knockdown of p300; curcumin (p300 inhibitor) treatment; cell migration and invasion assays Biochimica et biophysica acta. Gene regulatory mechanisms Medium 31154107
2019 ELOVL3 is required for production of C21:0–C29:0 fatty acids (including odd-chain and branched chain species) in meibomian glands; ELOVL3 ablation causes selective depletion of cholesteryl esters, wax esters, and cholesteryl esters of O-acylated ω-hydroxy fatty acids in tarsal plates, demonstrating ELOVL3's essential catalytic role in meibogenesis. Elovl3 knockout mice vs. wild-type; chromatographic and mass spectrometric lipid profiling of tarsal plate lipids; slit lamp examination; histological analysis of ocular tissues FASEB journal High 31208226
2019 Sustained rhythmic expression of hepatic Elovl3 requires coordination between the circadian clock (BMAL1) and androgen signaling; NR1D1 (RevErbα) binds the Elovl3 promoter in a circadian-dependent manner in vivo; castration abolishes Elovl3 levels in male liver but not circadian variation, while 5α-dihydrotestosterone induces Elovl3 in female livers and AML12 cells in a time- and androgen receptor-dependent manner. Bmal1 knockout mice; ChIP assay for NR1D1 binding at Elovl3 promoter across circadian time; castration experiments; 5α-dihydrotestosterone injection in female mice; flutamide (androgen receptor antagonist) treatment in AML12 cells; zeitgeber/circadian time series mRNA analysis The Journal of biological chemistry High 30862677
2021 ELOVL3 ablation reduces meibum melting temperature by ~8°C and increases meibum fluidity, demonstrating that ELOVL3-derived VLCFAs determine the thermotropic/physical properties of meibum; transcriptomic analysis of meibomian glands reveals that ELOVL3 loss dysregulates lipid biosynthesis, inflammation, and stress response gene networks. Elovl3 knockout mice; heat-stage polarized light microscopy for meibum melting temperature; histological examination; MG transcriptome analysis (RNA-seq); slit lamp examination FASEB journal Medium 33455016
2023 ZHX2 (zinc fingers and homeoboxes 2) transcription factor positively regulates Elovl3 expression in mouse liver; forced Elovl3 expression in human hepatoma cells reduces cell growth and causes cell cycle arrest in S-phase with reduced cyclin mRNA levels, demonstrating that ELOVL3-derived VLCFAs regulate hepatocyte proliferation and cell cycle progression. Mouse microarray and in vivo liver regeneration models; cell-based Elovl3 overexpression in hepatoma lines; cell growth assays; cell synchronization and cell cycle analysis; cyclin mRNA measurement; VLCFA profiling; Zhx2-null mouse livers American journal of physiology. Gastrointestinal and liver physiology Medium 37847682
2023 Hepatic-specific deletion of Elovl3 (via Cre/LoxP) does not alter body weight, liver mass, liver triglyceride content, lipid profiles, or hepatic lipogenic/oxidative gene expression under normal chow or high-fat diet, demonstrating that hepatic ELOVL3 alone is dispensable for liver lipid homeostasis (negative finding; the anti-obesity phenotype in global KO is attributable to extrahepatic ELOVL3 function). Liver-specific Elovl3 Cre/LoxP knockout mice; high-fat diet challenge; body weight and liver mass measurement; lipidomics; liver triglyceride assay; hepatic gene expression (qRT-PCR and Western blot); glucose tolerance test; ELOVL1 and ELOVL7 expression controls Biochemical and biophysical research communications Medium 37030067
2024 Testosterone/androgen receptor (AR) negatively regulates ELOVL3 transcription through an androgen response element (ARE) in the ELOVL3 promoter; AR overexpression suppresses ELOVL3 promoter activity, and ELOVL3 knockdown reduces lipid droplet accumulation and FASN expression while increasing ATGL mRNA in porcine preadipocytes. Porcine preadipocyte model with testosterone treatment; transcriptomic sequencing; dual-luciferase reporter assay with wild-type and ARE-mutant ELOVL3 promoter; AR overexpression; ELOVL3 siRNA knockdown; lipid droplet staining; FASN and ATGL mRNA analysis Animals Medium 39123669
2025 BAT-specific deletion of Elovl3 causes cold intolerance due to impaired BAT thermogenesis and defective mitochondrial cristae remodeling; lipidomics reveals that Elovl3 deficiency markedly reduces lysophosphatidylcholine, cardiolipin, and acylcarnitine levels in BAT, identifying ELOVL3-derived VLCFAs as required components of BAT phospholipid homeostasis that support UCP1 expression and mitochondrial remodeling during cold adaptation. BAT-specific Elovl3 Cre/LoxP knockout mice; cold exposure challenge; body temperature measurement; Ucp1 expression (qRT-PCR and Western blot); BAT histology; lipidomics analysis; mitochondrial ultrastructure (histological evaluation of cristae remodeling); muscle shivering assessment Journal of lipid research High 41202879
2026 USP25 deubiquitinase binds and stabilizes PARP1 through deubiquitination; PARP1 in turn promotes preadipocyte differentiation and maturation by regulating ELOVL3 expression, placing ELOVL3 downstream of a USP25–PARP1 axis in adipocyte differentiation. Usp25 knockout mice; 3T3-L1 adipocyte differentiation model; RNA sequencing; Co-immunoprecipitation of USP25 and PARP1; ubiquitination assay; PARP1 knockdown with Elovl3 expression readout; adipose tissue histology Journal of lipid research Medium 41692245

Source papers

Stage 0 corpus · 22 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 Role for ELOVL3 and fatty acid chain length in development of hair and skin function. The Journal of biological chemistry 162 14581464
2005 ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue. The Journal of biological chemistry 125 16326704
2010 Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 95 20605947
2019 The chromatin remodeling protein BRG1 links ELOVL3 trans-activation to prostate cancer metastasis. Biochimica et biophysica acta. Gene regulatory mechanisms 50 31154107
2005 Differential regulation of fatty acid elongation enzymes in brown adipocytes implies a unique role for Elovl3 during increased fatty acid oxidation. American journal of physiology. Endocrinology and metabolism 50 15855229
2012 Very long-chain-fatty acids enhance adipogenesis through coregulation of Elovl3 and PPARγ in 3T3-L1 cells. American journal of physiology. Endocrinology and metabolism 49 22436697
2008 Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology 43 18292190
2006 Elovl3: a model gene to dissect homeostatic links between the circadian clock and nutritional status. Journal of lipid research 41 17003504
2019 On the pivotal role of Elovl3/ELOVL3 in meibogenesis and ocular physiology of mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 38 31208226
2019 Coordination between the circadian clock and androgen signaling is required to sustain rhythmic expression of Elovl3 in mouse liver. The Journal of biological chemistry 30 30862677
2015 Vitamin D Regulates Fatty Acid Composition in Subcutaneous Adipose Tissue Through Elovl3. Endocrinology 29 26488808
2007 Norepinephrine and rosiglitazone synergistically induce Elovl3 expression in brown adipocytes. American journal of physiology. Endocrinology and metabolism 26 17726147
2018 Fatty acids promote bovine skeletal muscle satellite cell differentiation by regulating ELOVL3 expression. Cell and tissue research 23 29464364
2023 Hepatic ELOVL3 is dispensable for lipid metabolism in mice. Biochemical and biophysical research communications 10 37030067
2021 Physiological effects of inactivation and the roles of Elovl3/ELOVL3 in maintaining ocular homeostasis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 9 33455016
2024 Testosterone Inhibits Lipid Accumulation in Porcine Preadipocytes by Regulating ELOVL3. Animals : an open access journal from MDPI 5 39123669
2025 ELOVL3 regulates phospholipid homeostasis and thermogenesis in brown adipose tissue. Journal of lipid research 1 41202879
2024 Correlation and regression analysis of FA2H and ELOVL3 functional genes for cashmere fineness with production performance in Liaoning cashmere goat. Journal, genetic engineering & biotechnology 1 39674643
2023 Elongation of very long chain fatty acids-3 (Elovl3) is activated by ZHX2 and is a regulator of cell cycle progression. American journal of physiology. Gastrointestinal and liver physiology 1 37847682
2017 Effect of ELOVL3 expression on bovine skeletal muscle-derived satellite cell differentiation. Biochemical and biophysical research communications 1 28780350
2026 USP25 deficiency suppresses diet-induced obesity via ubiquitination and degradation of PARP1 and Elovl3 downregulation. Journal of lipid research 0 41692245
2026 Impact of Elovl3 Suppression on Sleep Deprivation-Induced Hepatic Steatosis and Glucose Intolerance in Mice. Cureus 0 42153054

Missed literature

Know a paper Affinage missed for ELOVL3? Flag it for the maintainers and the community.

No submissions yet.